GlassScriptPhysician profile
James W Hudson
NPI 1104852029
$5,801.69
in general payments reported to CMS, 2019-2025
35 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,736 · 2020: $1,302 · 2021: $587 · 2022: $489 · 2023: $374 · 2024: $156 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $2,730.00 | 2019-2020 | |
| Abbvie INC. | $627.39 | 2021-2025 | |
| Novo Nordisk INC | $556.75 | 2019-2024 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $324.22 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $258.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.07 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $145.58 | 2019-2023 | Trintellix |
| Lilly USA, LLC | $123.78 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $111.72 | 2019-2025 | |
| Eisai INC. | $59.88 | 2019-2021 | |
| Allergan, INC. | $56.72 | 2019-2020 | |
| Esperion Therapeutics, INC. | $55.90 | 2021-2022 | |
| Amarin Pharma, INC. | $52.63 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $51.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.72 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Medical-Surgical, INC. | $37.31 | 2023 | |
| Corium, LLC | $36.36 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $34.75 | 2021-2024 | Spravato |
| Inari Medical, INC. | $29.57 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2021-2022 | |
| Ibsa Pharma INC. | $28.40 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $25.89 | 2019 | |
| Shire North American Group INC | $21.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.98 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $17.23 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.29 | 2025 | Voquezna |
| Astellas Pharma US INC | $15.22 | 2019 | |
| Gilead Sciences, INC. | $15.01 | 2019 | |
| Shield Therapeutics INC | $14.50 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.08 | 2020 | |
| Currax Pharmaceuticals LLC | $12.71 | 2020 | |
| Sanofi Pasteur INC. | $12.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.09 | 2019 | |
| Glaxosmithkline, LLC. | $11.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.